Search Results
Mar 20, 2026, 12:11 ET Matrix Expands Its 2026 Brand Ambassador Roster with New Creative Powerhouses
joy and inclusivity.For media inquiries, including stylist or executive quotes, additional background on the ambassador program, ambassador bios, hi-res imagery, or samples, please contact [email protected]
More news about: Matrix
Mar 19, 2026, 21:00 ET D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
D3S-003, our differentiated KRAS G12D inhibitor addressing large unmet medical needs in pancreatic and colo-rectal cancers. These data highlight D3 Bio's strong scientific progress and commitment to advancing transformative therapies for patients with KRAS-driven cancers. We look forward to engaging with
More news about: D3 Bio
Mar 19, 2026, 08:00 ET Endevica Announces Spinout of Kalohexis to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases
X.About Endevica BioEndevica Bio is a world-leader in the discovery of first-in-class peptide drug candidates. Endevica Bio's proprietary technology platform, protected by a robust intellectual property portfolio, allows for the AI-assisted design of novel peptides to modulate
More news about: Endevica Bio
Mar 19, 2026, 08:00 ET Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases
effects.About Endevica BioEndevica Bio is a world-leader in the discovery of first-in-class peptide drug candidates. Endevica Bio's proprietary technology platform, protected by a robust intellectual property portfolio, allows for the AI-assisted design of novel peptides to modulate
More news about: Kalohexis
Mar 19, 2026, 07:00 ET Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Shanghai. These capabilities leverage China's strong drug discovery ecosystem anchored by both innovation and execution efficiency to advance Brii Bio's early-stage pipeline while driving long-term value creation. The Company plans to disclose additional details on its discovery strategy and pipeline
More news about: Brii Biosciences Limited
Mar 18, 2026, 10:00 ET A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
α-Klotho — while protecting the cells from immune rejection. It's backed by over 50 peer-reviewed publications and decades of development.Avaí Bio's dual-program approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, each leveraging the same Cell-in-a-Box® encapsulation
More news about: Equity Insider
Mar 18, 2026, 09:00 ET GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
study's p-value of 0.032 failed to meet the prespecified significance threshold of 0.025. Levi & Korsinsky, LLP is investigating whether Gossamer Bio's prior statements to investors about trial confidence, statistical power, and patient baseline characteristics were accurate when made.Shareholders
More news about: Levi & Korsinsky, LLP
Mar 17, 2026, 16:35 ET Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
Publications section of Nuvation Bio's website after the sessions. To learn more about Nuvation Bio, visit Booth #4459 at the AACR Annual Meeting.About ROS1+ NSCLCEach
More news about: Nuvation Bio Inc.
Mar 16, 2026, 10:01 ET Neuromyelitis Optica Spectrum Disorder Market Poised for Robust Expansion Through 2036 | DelveInsight
complement-dependent cytotoxicity while enhancing ADCC, and is currently under evaluation for autoimmune conditions such as NMOSD.RemeGen/Vor Bio's Telitacicept (RC18) is an innovative fusion protein developed for the treatment of autoimmune disorders. It is composed of the extracellular domain
More news about: DelveInsight Business Research, LLP
Mar 13, 2026, 19:53 ET NEDHSA Announces Virtual Opioid Education Series Addressing Maternal Health and Addiction
Register today and join us in making a meaningful impact.Additional details, including registration information and speaker bios, will be provided through the official event flyer.About Northeast Delta Human Services AuthorityThe Northeast Delta Human Services Authority
More news about: Northeast Delta Human Services Authority
Mar 13, 2026, 09:31 ET SafeSport Concludes International Symposia on Safeguarding in Sports
countries. The symposia propelled conversations on best practices and lessons learned. Here is more information on the international panelists, including bios, for both the
More news about: U.S. Center for SafeSport
Mar 13, 2026, 06:00 ET Best Online Learning Courses (2026): Coursera Named Leading Platform for Career-Focused Education by Expert Consumers
skill level, language, course type, and learning product, including Professional Certificates and Specializations. Course descriptions, instructor bios, and learner reviews support informed decision-making.This structured discovery process is particularly relevant as online education continues
More news about: ExpertConsumers.org
Mar 12, 2026, 08:30 ET Halozyme Appoints David Ramsay as Interim Chief Financial Officer
settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE®
More news about: Halozyme Therapeutics, Inc.
Mar 11, 2026, 09:00 ET 技嘉推出支援 Intel® Core™ Ultra 200S PLUS 系列處理器與 CQDIMM 技術的 Z890 PLUS 系列主機板
的配置，兼顧高容量與高速表現。透過優化主機板電路設計，技嘉有效降低記憶體通道負載並提升訊號完整性，確保系統在高負載環境下仍能維持高頻運作，記憶體速度最高可達 DDR5-10266。除了硬體層面的強化外，技嘉亦結合獨家的 D5 DUO X BIOS 調校技術，透過最佳化的時脈驅動架構，智能管理時序、訊號同步與電壓，進一步釋放 新一代Z890 平台的完整效能。為進一步提升整體表現，技嘉在 Z890 PLUS 系列主機板導入 BIOS 層級的效能增強功能 Ultra Turbo Mode，可透過一鍵調校處理器與 DRAM 設定。此系列產品亦承襲上世代的 D5 Bionic Corsa 技術，結合 AI 驅動的 AORUS AI Snatch 軟體、硬體設計與 HyperTune BIOS 韌體，提供使用者一鍵超頻 DDR5 記憶體的智能體驗。除了 DUO
More news about: GIGABYTE
Mar 11, 2026, 09:00 ET GIGABYTE Launches Z890 Plus Series Motherboards Supporting Intel Core Ultra 200S Plus Series Processors and CQDIMM Technology
workloads, boosting speed up to DDR5-10266. Complementing the hardware advancements is GIGABYTE's sophisticated D5 DUO X BIOS tuning technology. Through an optimized clock driver architecture, GIGABYTE's BIOS intelligently manages timing, signal synchronization, and voltage behavior to unleash potential performance.To
More news about: GIGABYTE
Mar 11, 2026, 09:00 ET GIGABYTE Launches Z890 Plus Series Motherboards Supporting Intel Core Ultra 200S Plus Series Processors and CQDIMM Technology
Complementing the hardware advancements is GIGABYTE's sophisticated D5 DUO X BIOS tuning technology. Through an optimized clock driver architecture, GIGABYTE's BIOS intelligently manages timing, signal synchronization, and voltage behavior to unleash potential performance.To
More news about: GIGABYTE
Mar 11, 2026, 09:00 ET GIGABYTE stellt neue Motherboards der Z890 Plus Serie vor, die Intel® Core™ Ultra 200S Plus Prozessoren und CQDIMM-Technologie unterstützen
bis zu DDR5-10266 zu erreichen. Ergänzt werden die Fortschritte bei der Hardware durch GIGABYTEs D5 DUO X BIOS-Tuning-Technologie. Durch eine optimierte Takttreiberarchitektur verwaltet GIGABYTEs BIOS auf intelligente Weise das Timing, die Signalsynchronisation und das Spannungsverhalten, um das Leistungspotenzial
More news about: GIGABYTE
Mar 11, 2026, 09:00 ET GIGABYTE lança placas-mãe da série Z890 Plus com suporte aos processadores Intel® Core™ Ultra 200S Plus e à tecnologia CQDIMM
para até DDR5-10266. Complementando os avanços de hardware, está a sofisticada tecnologia de ajuste de D5 DUO X BIOS da GIGABYTE. Por meio de uma arquitetura de clock driver otimizada, a BIOS da GIGABYTE gerencia de forma inteligente os timings, a sincronização de sinal e o comportamento da voltagem para
More news about: GIGABYTE
Mar 11, 2026, 09:00 ET GIGABYTE presenta las tarjetas madre de la serie Z890 Plus compatibles con los procesadores Intel® Core™ Ultra 200S Plus y la tecnología CQDIMM
lo cual aumenta la velocidad hasta DDR5-10266. La sofisticada tecnología de ajuste de BIOS de GIGABYTE complementa los avances de hardware. Mediante una arquitectura de controlador de reloj optimizada, el D5 DUO X BIOS de GIGABYTE gestiona de manera inteligente la temporización, la sincronización de la
More news about: GIGABYTE
Mar 11, 2026, 09:00 ET GIGABYTE lanza las placas base Z890 Plus para Intel® Core™ Ultra 200S Plus y tecnología CQDIMM
DDR5-10266. Además, GIGABYTE completa todos estos avances en hardware con una sofisticada tecnología de configuración del D5 DUO X BIOS. Mediante una arquitectura de reloj optimizada, la BIOS de GIGABYTE gestiona de forma inteligente los plazos, la sincronización de señales y la tensión para liberar todo el potencial
More news about: GIGABYTE
Mar 11, 2026, 09:00 ET GIGABYTE lance les cartes mères de la série Z890 Plus prenant en charge les processeurs Intel® Core™ Ultra 200S Plus et la technologie CQDIMM
DDR5-10266. En complément des avancées matérielles, GIGABYTE propose une technologie sophistiquée de réglage du BIOS D5 DUO X. Grâce à une architecture de pilote d'horloge optimisée, le BIOS de GIGABYTE gère intelligemment le timing, la synchronisation des signaux et le comportement de la tension pour
More news about: GIGABYTE
Mar 11, 2026, 09:00 ET 기가바이트, Intel® Core™ Ultra 200S Plus 프로세서 및 CQDIMM 기술 지원 Z890 Plus 시리즈 메인보드 출시
최대 DDR5-10266 속도를 구현한다. 이러한 하드웨어의 발전에 더해 기가바이트의 정교한 D5 DUO X BIOS 튜닝 기술이 적용됐다. 최적화된 클록 드라이버 아키텍처를 기반으로 BIOS가 타이밍, 신호 동기화, 전압을 지능적으로 관리해 메모리의 잠재 성능을 최대치로 끌어낸다.기가바이트는 Z890 Plus 시리즈에 울트라 터보 모드(Ultra Turbo Mode)를 적용해 성능을 한층 더 끌어올렸다. 이는 BIOS 수준의 성능 향상 기능으로, 간단한 클릭만으로 프로세서와 DRAM 설정을 지능적으로 최적화한다. 또한 이전
More news about: GIGABYTE
Mar 11, 2026, 09:00 ET GIGABYTE ra mắt dòng Bo mạch chủ Z890 Plus Series hỗ trợ bộ xử lý Intel® Core™ Ultra 200S Plus và công nghệ CQDIMM
tăng tốc độ lên đến DDR5-10266. Bổ sung cho các cải tiến phần cứng là công nghệ tinh chỉnh D5 DUO X BIOS tinh vi của GIGABYTE. Thông qua kiến trúc trình điều khiển xung nhịp được tối ưu hóa, BIOS của GIGABYTE có thể quản lý thời gian thông minh, đồng bộ hóa tín hiệu, và kiểm soát điện áp, từ đó
More news about: GIGABYTE
Mar 11, 2026, 08:59 ET Immorta Bio Demonstrates Dramatic Lifespan Extension in Aging Mouse Models; Research Accepted for Presentation at AAI's IMMUNOLOGY2026
function, supporting the broader therapeutic potential of the platform across multiple age-related conditions.These findings support Immorta Bio's strategy of addressing two fundamental drivers of aging biology: the accumulation of senescent cells and the progressive loss of regenerative capacity.SenoVax™
More news about: Immorta Bio Inc.
Mar 10, 2026, 17:31 ET CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
feasibility are being investigated in the ATALANTA-1 Phase I/II trial in patients with relapsed or refractory non-Hodgkin lymphoma.Cabaletta Bio's Rese-cel is a fully human CD19-targeting CAR-T therapy that incorporates a 4-1BB co-stimulatory domain. Cabaletta is evaluating it in the RESET
More news about: DelveInsight Business Research, LLP